New Hope For Those Battling A Genetic Disease

Saturday, March 1, 2014

(NAPSA)—There’s hopeful news for those whoare at risk for a rare disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. A biotechnology companyis committed to finding a treatment and is working toward delivering a significant improvement in the health and quality of life to future generations living with this rare genetic disorder. The Disease X-linked hypohidrotic ectodermal dysplasia, or XLHED, is the disease and the companyis Edimer Pharmaceuticals. XLHED is a rare genetic disorder that results in abnormal development of teeth, hair and glandular structures in the skin and mucosal membranes. Patients affected by the disease often contend with lifelong dental An effort is under way to combat a rare genetic disorder that results in the abnormal development of a child’s teeth, hair and skin. e Phase 1 of the adult safety study was completed in spring of 2018. e Phase 2, the newborn XLHED clinical study, began enrolling applicants in the late summerof 2013 andis ongoing. For a list of active studies on the disease and the status of each, scaly skin, premature hair loss and other related health complications associated with lack of functional sweat and secretory glands. A Potential Treatment Edimer is developing EDI200 as a potential treatment for future generations living with XLHED. In preclinical studies, EDI200 has been shown to greatly enhance the development of hair, teeth, skin and some glandular structures. The studies also indi- visit www.clinicaltrials.gov. Ways To Get Involved Those who wish to get involved in the clinical study process can register at XLHEDnetwork.com. To learn more, you can find and follow the company on Face book.com/EdimerPharmaor visit the company’s website at www.edi merpharma.com. Those who wish to qualify for free genetic testing to see if they are at risk can visit Have the Conversation at www.havetheconvo.com. a lifelong benefit. cal trial process or to partici- currently under way: ramsey@edimerpharma.com. issues, respiratory infections, cate early treatment mayresult in Clinical trials in humans are For information on the clini- pate, contact Ramsey Johnson at

--- PHOTOS ---

File: 20190731-235649-20190731-235646-84389.pdf.jpg

--- FILES ---

File: 20190731-235646-84389.pdf